港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

科倫博泰生物-B

285.400

-3.600-1.25%

成交量：81.19萬

成交額：2.33億

市值：647.86億

市盈率：-222.78

高：294.000

開：285.000

低：275.000

收：289.000

資料載入中...

總覽公司新聞公告

《大行》招銀國際下調科倫博泰(06990.HK)目標價至227.88元評級“買入”

阿斯达克财经

招銀國際：維持科倫博泰生物-B(06990)“買入”評級目標價227.88港元

智通财经网

國金證券：市場對醫藥左側反轉的重視上升呼吸道感染上行關注相關板塊

和鉑醫藥(02142.HK)科倫博泰(06990.HK)聯合開發產品WIN378授出獨家許可

阿斯达克财经

科倫博泰生物-B與Windward Bio AG就SKB378/HBM9378訂立獨佔性許可協議

和鉑醫藥-B(02142)及科倫博泰(06990)與WINDWARD BIO AG就HBM9378/SKB378訂立獨家授權協議

招銀國際：政策持續發力看好中國醫藥估值反彈

【券商聚焦】招銀國際指醫藥行業受益於海外降息以及國內宏觀環境改善有望在2025年跑贏市場

科倫博泰生物(06990.HK)核心產品博度曲妥珠單抗新藥申請獲受理

阿斯达克财经

科倫博泰生物-B(06990)：核心產品博度曲妥珠單抗的新藥申請獲國家藥監局受理

國聯證券2025年醫藥生物投資策略：增量看空間存量看結構

國金證券：重磅政策出爐創新仍是最重要方向醫藥健康行業進入業績窗口關注反轉預期

異動解讀 | 注射液上市獲批科倫博泰生物-B盤中大漲5%

科倫博泰生物-B盤中異動早盤股價大漲5.02%

【港股通】科倫博泰生物-B逆市升逾4% 抗PD-L1塔戈利單抗獲國家藥監局批准上市

【港股異動 | 科倫博泰生物-B(06990.HK)現漲超4% 】科倫博泰生物-B(06990.HK)早盤漲超4%，截至發稿，漲4.53%，報170.7港元，成交額944.08萬港元。

港股異動 | 科倫博泰生物-B(06990)現漲超4% 國家藥監局批准塔戈利單抗注射液上市

年度盤點｜2024年的港股醫藥生物公司跌多漲少，漲跌幅最大前十公司分別有何共性

全球首款CLDN18.2靶向藥國內獲批上市，熱門靶點競爭格局幾何

科倫博泰(06990.HK)抗PD-L1塔戈利單抗獲國家藥監局批准上市

阿斯达克财经

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/06990/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06990","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科倫博泰生物-B","latestPrice":285.4,"timestamp":1744877289037,"preClose":289,"halted":0,"volume":811904,"delay":0,"floatShares":131000000,"shares":227000000,"eps":-1.2811130563505986,"marketStatus":"復活節星期一休市","change":-3.6,"latestTime":"04-17 16:08:09","open":285,"high":294,"low":275,"amount":232778521,"amplitude":0.065744,"askPrice":286.4,"askSize":300,"bidPrice":285.4,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-1.2811130563505986,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1745285400000},"marketStatusCode":7,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":289,"openAndCloseTimeList":[[1744853400000,1744862400000],[1744866000000,1744876800000]],"volumeRatio":1.0355934219983844,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","floatShares":131000000,"roa":"-3.41%","roe":"-9.46%","lyrEps":-1.281113,"volumeRatio":1.0355934219983844,"shares":227000000,"dividePrice":0,"high":294,"amplitude":0.065744,"preClose":289,"low":275,"week52Low":120.2,"pbRate":"18.40","psRate":"31.49","week52High":346,"institutionHeld":0,"latestPrice":285.4,"eps":-1.2811130563505986,"divideRate":0,"volume":811904,"delay":0,"ttmEps":-1.2811130563505986,"open":285,"prevYearClose":163.3,"prevWeekClose":285.4,"prevMonthClose":290.8,"prevQuarterClose":290.8,"fiveDayClose":280.8,"twentyDayClose":259.4,"sixtyDayClose":162.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06990\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2503292943","title":"《大行》招銀國際下調科倫博泰(06990.HK)目標價至227.88元  評級“買入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2503292943","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503292943?lang=zh_tw&edition=fundamental","pubTime":"2025-01-13 15:39","pubTimestamp":1736753940,"startTime":"0","endTime":"0","summary":"招银国际发表报告指，SKB378是科伦博泰与和铂医药共同开发的TSLP单抗，现已对外授权给Windward公司。交易价值最高可达9.7亿美元，含4,500万美元的首付款和近期付款，将以现金和 Windward母公司股权支付，科伦博泰与和铂医药将平分款项。SKB378可用于治疗哮喘、慢性阻塞性肺疾病等免疫疾病。招银国际维持科伦博泰“买入”评级。同时将公司目标价由243.38港元降至 227.88港元。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230628160655871_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230628160655871_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1409934/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06990"],"gpt_icon":0},{"id":"2503347136","title":"招銀國際：維持科倫博泰生物-B(06990)“買入”評級 目標價227.88港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503347136","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503347136?lang=zh_tw&edition=fundamental","pubTime":"2025-01-13 11:46","pubTimestamp":1736740019,"startTime":"0","endTime":"0","summary":"招银国际看好科伦博泰生物-B(06990)SKB264在2025年8-10亿元人民币的销售目标。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20250113/20250113114723_93605.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20250113/20250113114723_93605.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1236609.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06990"],"gpt_icon":0},{"id":"2503345720","title":"國金證券：市場對醫藥左側反轉的重視上升 呼吸道感染上行關注相關板塊","url":"https://stock-news.laohu8.com/highlight/detail?id=2503345720","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503345720?lang=zh_tw&edition=fundamental","pubTime":"2025-01-13 11:36","pubTimestamp":1736739368,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，近期国内北方和部分南方地区流感和其他呼吸道感染比例持续上升，建议密切跟踪传染病态势，重点关注体外诊断、中药和OTC、疫苗、仿制药等板块。中国药企创新实力及其成长空间还远未被资本市场所充分认知。新适应证的获批，标志着佳达修成为中国境内首个且目前唯一获批、可适用于男性的HPV疫苗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1236600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","LU0196878994.USD","BK0201","BK1161","BK1574","BK0183","06990","600109","BK0188","159938","BK1515","09939","BK0276","BK0012"],"gpt_icon":0},{"id":"2502336981","title":"和鉑醫藥(02142.HK)科倫博泰(06990.HK)聯合開發產品WIN378授出獨家許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2502336981","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502336981?lang=zh_tw&edition=fundamental","pubTime":"2025-01-12 20:23","pubTimestamp":1736684580,"startTime":"0","endTime":"0","summary":"和铂医药－Ｂ(02142.HK) 公布，连同科伦博泰生物－Ｂ(06990.HK) 作为授权方，与Windward Bio订立独家授权协议，就授权方联合开发的抗胸腺基质淋巴细胞生成素(TSLP)单克隆抗体HBM9378/SKB378授予Windward Bio全球独家许可，以在大中华区及若干东南亚及西亚国家以外生产、开发、使用、推广、销售、许诺销售、进口及以其他方式商业化。授权方有权收取最多合共9.7亿美元预付款及里程碑付款以及占净销售额个位数到双位数百分比的分层特许权使用费。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-10 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180119144847470_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180119144847470_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1409684/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06990","02142","LU0196878994.USD","BK1161","BK1583","BK1574"],"gpt_icon":0},{"id":"2502869737","title":"科倫博泰生物-B與Windward Bio AG就SKB378/HBM9378訂立獨佔性許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2502869737","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502869737?lang=zh_tw&edition=fundamental","pubTime":"2025-01-10 21:47","pubTimestamp":1736516821,"startTime":"0","endTime":"0","summary":"根据许可协议的条款及条件，Windward Bio获授予SKB378/HBM9378在全球的研究、开发、生产及商业化的独家许可。根据许可协议的条款及条件，若Windward Bio近期发生控制权变更或与第三方订立分许可协议，许可方亦有资格向Windward Bio收取额外款项。许可协议将结合许可方与Windward Bio的研发、生产及商业化能力，支持SKB378/HBM9378的商业化进程，并建立有利的市场地位。许可协议的实施还将使公司能够将SKB378/HBM9378推向全球市场，最大化其商业价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501102151409861dd3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501102151409861dd3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","BK1161","LU0196878994.USD","02142","06990"],"gpt_icon":0},{"id":"2502863377","title":"和鉑醫藥-B(02142)及科倫博泰(06990)與WINDWARD BIO AG就HBM9378/SKB378訂立獨家授權協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2502863377","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502863377?lang=zh_tw&edition=fundamental","pubTime":"2025-01-10 21:04","pubTimestamp":1736514297,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B 公布，公司及科伦博泰已与 Windward Bio AG就授权方联合开发的抗胸腺基质淋巴细胞生成素单克隆抗体HBM9378/SKB378订立独家授权协议。4500万美元的预付款及近期里程碑付款包括现金付款及Windward Bio母公司的股权。基于上述，授权协议的订立将授权方与Windward Bio 的研发、生产及商业化能力整合在一起，为HBM9378/SKB378走向商业化提供支持并确立有利市场地位。授权协议的实施亦让公司能够将HBM9378/SKB378推向全球市场，令其商业价值得到最大化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1236337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","02142","LU1169590202.USD","LU0196878994.USD","BK4585","LU1169589451.USD","BK1583","AG","06990","BIO","BK4121","BK4210","BK1574","BK1161"],"gpt_icon":0},{"id":"2501371720","title":"招銀國際：政策持續發力 看好中國醫藥估值反彈","url":"https://stock-news.laohu8.com/highlight/detail?id=2501371720","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501371720?lang=zh_tw&edition=fundamental","pubTime":"2025-01-08 16:34","pubTimestamp":1736325258,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，受益于海外降息以及国内宏观环境改善，医药作为高弹性行业有望在2025年跑赢市场。随着医疗设备招标大幅复苏，看好招标恢复的持续性，看好行业估值修复。国办再发文支持创新药械1月3日，国务院办公厅发布《关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见》。医疗设备招标大幅复苏，看好招标恢复的持续性根据众成数科统计，12月全国医疗器械公开招中标市场规模同比增长37%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1234865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1583","02359","BK0250","BK1576","LU0320764599.SGD","LU1969619763.USD","BK0188","01801","LU2488822045.USD","LU1046422090.SGD","BK0028","BK1141","LU2125910500.SGD","02367","BK1207","BK0082","LU2045819591.USD","BK0175","LU0052750758.USD","01530","LU0196878994.USD","BK0185","06990","BK0010","BK1593","LU2328871848.SGD","LU2242644610.SGD","600056","LU0708995583.HKD","BK1589"],"gpt_icon":0},{"id":"2501471482","title":"【券商聚焦】招銀國際指醫藥行業受益於海外降息以及國內宏觀環境改善 有望在2025年跑贏市場","url":"https://stock-news.laohu8.com/highlight/detail?id=2501471482","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501471482?lang=zh_tw&edition=fundamental","pubTime":"2025-01-08 15:41","pubTimestamp":1736322113,"startTime":"0","endTime":"0","summary":"近期，中国创新药出海交易继续快速增长，例如信达生物和恒瑞医药分别与罗氏和IDEAYA Biosciences达成了关于DLL3ADC的海外授权交易，交易总额均超过10亿美金。该行认为，受益于海外降息以及国内宏观环境改善，医药作为高弹性行业有望在2025年跑赢市场。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1951004","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","06990","06160","01530","BK1588","BK1593","LU2125910500.SGD","BK1583","LU2328871848.SGD","BK1576","LU0708995583.HKD","LU2045819591.USD","BK1161","LU0052750758.USD","BK1589","LU2488822045.USD","LU0320764599.SGD","HK0000934320.USD","BK1141","01801","LU1046422090.SGD","LU0196878994.USD","LU0588546209.SGD","LU2242644610.SGD","BK1500","LU1969619763.USD","02367","BK1207","LU0307460666.USD"],"gpt_icon":0},{"id":"2501836077","title":"科倫博泰生物(06990.HK)核心產品博度曲妥珠單抗新藥申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2501836077","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501836077?lang=zh_tw&edition=fundamental","pubTime":"2025-01-07 23:01","pubTimestamp":1736262060,"startTime":"0","endTime":"0","summary":"科伦博泰生物－Ｂ(06990.HK) 公布，靶向人类表皮生长因子受体2(HER2)的抗体药物偶联物(ADC)博度曲妥珠单抗的新药申请已获中国国家药品监督管理局药品审评中心受理，用于既往至少接受过一种抗HER2治疗的HER2阳性不可切除或转移性乳腺癌成人患者的治疗。博度曲妥珠单抗是公司研发的创新HER2 ADC。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-07 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230904161537733_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230904161537733_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1408574/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2501271833","title":"科倫博泰生物-B(06990)：核心產品博度曲妥珠單抗的新藥申請獲國家藥監局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2501271833","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501271833?lang=zh_tw&edition=fundamental","pubTime":"2025-01-07 18:58","pubTimestamp":1736247515,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B 发布公告，靶向人类表皮生长因子受体2的抗体药物偶联物博度曲妥珠单抗的新药申请(该申请)已获中国国家药品监督管理局药品审评中心受理，用于既往至少接受过一种抗HER2治疗的HER2阳性不可切除或转移性乳腺癌成人患者的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1234496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2501829224","title":"國聯證券2025年醫藥生物投資策略：增量看空間 存量看結構","url":"https://stock-news.laohu8.com/highlight/detail?id=2501829224","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501829224?lang=zh_tw&edition=fundamental","pubTime":"2025-01-07 16:13","pubTimestamp":1736237583,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国联证券发布研报称，展望2025年医药生物行业，从增量上看，需关注医保、自费和出海三大空间长期发展；存量上看，则需要关注医药与医疗回归本质。全球TOP20药企的销售额前100的品种专利期还有5年的只占31%，需求确定，国内IND品种数量和质量都具备出海的基础，有望延续授权引出的趋势；其二，左侧资产的估值修复。投资建议：高质量创新药出海及左侧资产修复2025年关注两条核心投资主线：高质量创新药出海。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1234328.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","000808.SH","LU0348783233.USD","LU1794554557.SGD","LU0417516571.SGD","LU0348784397.USD","BK1574","IE00B543WZ88.USD","01801","601456","LU0196878994.USD","163118","BK1564","BK1147","LU1969619763.USD","BK0276","LU2328871848.SGD","BK1583","06990","LU1720050803.USD","01456","IE00BPRC5H50.USD","09926","IE00B5MMRT66.SGD","BK1589","LU2488822045.USD"],"gpt_icon":0},{"id":"2501047884","title":"國金證券：重磅政策出爐創新仍是最重要方向 醫藥健康行業進入業績窗口關注反轉預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2501047884","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501047884?lang=zh_tw&edition=fundamental","pubTime":"2025-01-06 15:56","pubTimestamp":1736150187,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，创新是2025医药产业投资的最大政策利好方向。医疗服务及消费医疗：医保监管促进行业可持续发展，固生堂业务版图快速拓展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1233751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0183","BK0188","BK1161","BK0276","BK0201","BK0028","LU0196878994.USD","06990","600109"],"gpt_icon":0},{"id":"1102898989","title":"異動解讀 | 注射液上市獲批 科倫博泰生物-B盤中大漲5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102898989","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102898989?lang=zh_tw&edition=fundamental","pubTime":"2025-01-02 10:22","pubTimestamp":1735784542,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B(06990)今日盘中大涨5.02%,引起了市场的广泛关注。\n\n消息面上,公司发布公告称,其用于治疗复发或转移性鼻咽癌的创新药物塔戈利单抗注射液(科泰莱)已获国家药品监督管理局批准在中国上市。这一阶段性里程碑事件反映了公司在医药创新领域的进展,为鼻咽癌患者提供了新的治疗选择方案。\n\n塔戈利单抗是一种人源化单克隆抗体,可特异性结合细胞程序性死亡配体-1,阻断其与程序性死亡受体-1的相互作用,从而恢复免疫细胞对肿瘤细胞的抑制作用。该品种上市前景广阔,有望为公司创造新的利润增长点。市场对此表示了积极评价,导致公司股价在盘中出现明显上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06990"],"gpt_icon":0},{"id":"2500964582","title":"科倫博泰生物-B盤中異動 早盤股價大漲5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2500964582","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500964582?lang=zh_tw&edition=fundamental","pubTime":"2025-01-02 10:20","pubTimestamp":1735784403,"startTime":"0","endTime":"0","summary":"2025年01月02日早盘10时20分，科伦博泰生物-B股票出现波动，股价急速上涨5.02%。截至发稿，该股报171.500港元/股，成交量15.354万股，换手率0.12%，振幅6.55%。科伦博泰生物-B股票所在的生物技术行业中，整体跌幅为0.72%。科伦博泰生物-B公司简介：四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250102102004a2122fbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250102102004a2122fbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2500961859","title":"【港股通】科倫博泰生物-B逆市升逾4% 抗PD-L1塔戈利單抗獲國家藥監局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2500961859","media":"金吾资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500961859?lang=zh_tw&edition=fundamental","pubTime":"2025-01-02 09:52","pubTimestamp":1735782765,"startTime":"0","endTime":"0","summary":"金吾财讯 | 科伦博泰生物-B 早盘股价逆市走高，截至发稿，报170港元，涨4.1%，成交额927.09万港元。消息面上，公司发布公告，公司用于治疗既往接受过2线及以上化疗失败的复发或转移性鼻咽癌患者的靶向程序性细胞死亡配体1的创新人源化单克隆抗体塔戈利单抗（科泰莱）已获中国国家药品监督管理局批准于中国上市。同时，塔戈利单抗具有可管理的安全性，3级免疫相关不良事件为3.9%，未观察到3级以上免疫相关不良事件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010209531598583bb1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010209531598583bb1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","07226","HSCEI","BK1161","HSTECH","LU0196878994.USD"],"gpt_icon":0},{"id":"2500108969","title":"【港股異動 | 科倫博泰生物-B(06990.HK)現漲超4% 】科倫博泰生物-B(06990.HK)早盤漲超4%，截至發稿，漲4.53%，報170.7港元，成交額944.08萬港元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2500108969","media":"金融界","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500108969?lang=zh_tw&edition=fundamental","pubTime":"2025-01-02 09:52","pubTimestamp":1735782730,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B(06990.HK)早盘涨超4%，截至发稿，涨4.53%，报170.7港元，成交额944.08万港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/02095247024879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2500695579","title":"港股異動 | 科倫博泰生物-B(06990)現漲超4% 國家藥監局批准塔戈利單抗注射液上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2500695579","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500695579?lang=zh_tw&edition=fundamental","pubTime":"2025-01-02 09:46","pubTimestamp":1735782382,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B早盘涨超4%，截至发稿，涨4.53%，报170.7港元，成交额944.08万港元。消息面上，科伦博泰生物发布公告，公司用于治疗既往接受过2线及以上化疗失败的复发或转移性鼻咽癌患者的靶向程序性细胞死亡配体1的创新人源化单克隆抗体塔戈利单抗(科泰莱)已获国家药监局批准于中国上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1232249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 科伦博泰生物-B(06990)现涨超4% 国家药监局批准塔戈利单抗注射液上市","news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2500988151","title":"年度盤點｜2024年的港股醫藥生物公司跌多漲少，漲跌幅最大前十公司分別有何共性","url":"https://stock-news.laohu8.com/highlight/detail?id=2500988151","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500988151?lang=zh_tw&edition=fundamental","pubTime":"2025-01-01 18:21","pubTimestamp":1735726876,"startTime":"0","endTime":"0","summary":"刚刚过去的2024年，港股医药生物市场中的106只个股，股价（后复权）累计实现上涨的有26只，占比约25%。这里的医药生物市场，囊括了化学制药、中药、生物制品、医药商业、医疗器械、医疗服务这些细分市场。从涨幅最大或者跌幅最大的前十只个股来看，均以18A药企（港交所18A规则上市的公司）为主。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202501013284563250.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501013284563250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01681","LU0196878994.USD","01541","06996","09995","LU2488822045.USD","BK1100","YANG","BK1583","IE00B5MMRT66.SGD","BK1515","HSCEI","LU2328871848.SGD","02877","06185","07226","02415","09886","LU1969619763.USD","06855","IE00B543WZ88.USD","06990","BK1587","01952","02407","BK1574","LU1720050803.USD","BK1142","09926","09877","09939","02511","02257","BK1189","BK1585","BK1191","06998","BK1606","IE00BPRC5H50.USD","LU0417516571.SGD","02171","BK1161","LU1794554557.SGD","01167","HSTECH","BK1247","LU0348783233.USD","LU0348784397.USD","03933"],"gpt_icon":0},{"id":"2500612310","title":"全球首款CLDN18.2靶向藥國內獲批上市，熱門靶點競爭格局幾何","url":"https://stock-news.laohu8.com/highlight/detail?id=2500612310","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500612310?lang=zh_tw&edition=fundamental","pubTime":"2025-01-01 00:02","pubTimestamp":1735660967,"startTime":"0","endTime":"0","summary":"12月31日，国家药品监督管理局官网显示，安斯泰来申报的进口新药注射用佐妥昔单抗（商品名：威络益）上市，用于局部晚期不可切除或转移性胃或胃食管交界处（GEJ）腺癌患者的一线治疗。佐妥昔单抗是一款靶向治疗药物，为安斯泰来自主研发的全球首款CLDN18.2的IgG1单抗。该药物通过特异性结合CLDN18.2，增强免疫系统对肿瘤细胞的识别和攻击，从而抑制肿瘤生长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202501013284293845.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501013284293845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0196878994.USD","06990","06628","BK1587","BK1589","LU2488822045.USD","LU1969619763.USD","02171","BK1161","BK1574","BK1585","LU2328871848.SGD","01801","BK1583"],"gpt_icon":0},{"id":"2495182616","title":"科倫博泰(06990.HK)抗PD-L1塔戈利單抗獲國家藥監局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2495182616","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495182616?lang=zh_tw&edition=fundamental","pubTime":"2024-12-31 22:04","pubTimestamp":1735653840,"startTime":"0","endTime":"0","summary":"科伦博泰生物－Ｂ(06990.HK) 公布，公司用于治疗既往接受过2线及以上化疗失败的复发或转移性鼻咽癌患者的靶向程序性细胞死亡配体1(PD-L1)创新人源化单克隆抗体塔戈利单抗(科泰莱)已获中国国家药品监督管理局批准上市。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-31 12:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1407173/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06990\",params:#limit:5,,,undefined,":[{"date":"2025-03-24","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"盤後","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-19","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"盤後","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-03-25","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null},{"date":"2023-08-28","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693186200000,"name":null,"time":"","dateTimestamp":1693152000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06990\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06990\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2941,"buy":0.7059,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7059,"analysts":17,"updateTime":1744646400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06990\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06990","date":"2025-04-17","current":-228.611836,"percent":0.03653,"low":-257.850518,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"high":-21.029201,"avg":-97.473315,"sd":62.021902,"marketCap":64862287200},"quantilePoints":[{"date":"2023-07-14","current":-21.13661,"twenty":-21.950454,"median":-21.915957,"eighty":-21.591449,"marketCap":14244687534},{"date":"2023-07-21","current":-23.970152,"twenty":-21.950454,"median":-21.798359,"eighty":-21.186829,"marketCap":16079230625},{"date":"2023-07-28","current":-25.171471,"twenty":-24.928642,"median":-21.953758,"eighty":-21.326081,"marketCap":16867005011},{"date":"2023-08-04","current":-23.795235,"twenty":-24.81024,"median":-23.425444,"eighty":-21.637654,"marketCap":15971316326},{"date":"2023-08-11","current":-25.354634,"twenty":-24.81024,"median":-23.323535,"eighty":-21.856149,"marketCap":16921892522},{"date":"2023-08-18","current":-27.290696,"twenty":-25.136334,"median":-23.811022,"eighty":-21.920213,"marketCap":18083628667},{"date":"2023-08-25","current":-27.955027,"twenty":-25.91111,"median":-24.066367,"eighty":-21.957062,"marketCap":18532979440},{"date":"2023-09-01","current":-41.23344,"twenty":-27.36684,"median":-24.766756,"eighty":-21.989236,"marketCap":16768455673},{"date":"2023-09-08","current":-41.179226,"twenty":-40.625811,"median":-24.994187,"eighty":-22.159386,"marketCap":16549260174},{"date":"2023-09-15","current":-42.756679,"twenty":-41.200358,"median":-25.354634,"eighty":-22.761005,"marketCap":17316444421},{"date":"2023-09-22","current":-42.808543,"twenty":-42.12743,"median":-25.915972,"eighty":-23.169807,"marketCap":17261645546},{"date":"2023-09-29","current":-41.568511,"twenty":-42.347449,"median":-27.197776,"eighty":-23.343916,"marketCap":16790375223},{"date":"2023-10-06","current":-41.914184,"twenty":-42.346401,"median":-27.481057,"eighty":-23.57336,"marketCap":16921892522},{"date":"2023-10-13","current":-45.021843,"twenty":-42.393899,"median":-34.166325,"eighty":-23.80155,"marketCap":18149387317},{"date":"2023-10-20","current":-39.509362,"twenty":-42.529229,"median":-40.304828,"eighty":-23.874674,"marketCap":15902633452},{"date":"2023-10-27","current":-41.923505,"twenty":-42.45246,"median":-40.317099,"eighty":-23.977981,"marketCap":16867093648},{"date":"2023-11-03","current":-44.17615,"twenty":-43.157759,"median":-40.968576,"eighty":-24.032126,"marketCap":17820594068},{"date":"2023-11-10","current":-48.451746,"twenty":-43.729096,"median":-41.213927,"eighty":-24.147781,"marketCap":19541278735},{"date":"2023-11-17","current":-48.422639,"twenty":-44.163404,"median":-41.246315,"eighty":-24.349478,"marketCap":19705675360},{"date":"2023-11-24","current":-47.973827,"twenty":-44.628759,"median":-41.529173,"eighty":-24.780872,"marketCap":19683755810},{"date":"2023-12-01","current":-50.941262,"twenty":-45.174782,"median":-41.90853,"eighty":-24.844962,"marketCap":20987969029},{"date":"2023-12-08","current":-50.880899,"twenty":-46.685504,"median":-41.9817,"eighty":-24.922954,"marketCap":20878371279},{"date":"2023-12-15","current":-53.058458,"twenty":-47.438439,"median":-42.172758,"eighty":-25.124621,"marketCap":21897630350},{"date":"2023-12-22","current":-55.272951,"twenty":-48.26932,"median":-42.355666,"eighty":-25.208104,"marketCap":22796331896},{"date":"2023-12-29","current":-54.398289,"twenty":-48.483234,"median":-42.389893,"eighty":-25.318001,"marketCap":22555216847},{"date":"2024-01-05","current":-54.305497,"twenty":-48.692055,"median":-42.518207,"eighty":-25.505631,"marketCap":22357940898},{"date":"2024-01-12","current":-58.852865,"twenty":-49.706536,"median":-42.808543,"eighty":-25.777515,"marketCap":24243022189},{"date":"2024-01-19","current":-48.649703,"twenty":-50.614438,"median":-43.44751,"eighty":-25.920835,"marketCap":20012549058},{"date":"2024-01-26","current":-45.202208,"twenty":-50.432693,"median":-43.523908,"eighty":-26.320623,"marketCap":18522019665},{"date":"2024-02-02","current":-38.832469,"twenty":-50.323187,"median":-43.65215,"eighty":-26.948338,"marketCap":15891673677},{"date":"2024-02-09","current":-43.972121,"twenty":-49.706536,"median":-43.780393,"eighty":-27.253528,"marketCap":18083628667},{"date":"2024-02-16","current":-51.156498,"twenty":-50.095577,"median":-43.99523,"eighty":-27.328768,"marketCap":21042767904},{"date":"2024-02-23","current":-57.052501,"twenty":-50.855188,"median":-44.095348,"eighty":-27.575851,"marketCap":23344320643},{"date":"2024-03-01","current":-55.517903,"twenty":-51.144997,"median":-44.174132,"eighty":-27.979787,"marketCap":22730573246},{"date":"2024-03-08","current":-62.556972,"twenty":-52.587613,"median":-44.308071,"eighty":-30.229554,"marketCap":25623953833},{"date":"2024-03-15","current":-80.340969,"twenty":-54.14227,"median":-44.794506,"eighty":-38.844663,"marketCap":32879324850},{"date":"2024-03-22","current":-87.812662,"twenty":-54.39157,"median":-45.089055,"eighty":-38.957109,"marketCap":35904222736},{"date":"2024-03-28","current":-54.646477,"twenty":-54.498503,"median":-45.202208,"eighty":-39.211798,"marketCap":33975302345},{"date":"2024-04-05","current":-48.790889,"twenty":-54.557693,"median":-45.399289,"eighty":-39.390336,"marketCap":30314737511},{"date":"2024-04-12","current":-51.407626,"twenty":-54.48688,"median":-46.006494,"eighty":-39.95604,"marketCap":31958703754},{"date":"2024-04-19","current":-48.134373,"twenty":-54.430626,"median":-46.386128,"eighty":-40.284427,"marketCap":29898266063},{"date":"2024-04-26","current":-71.709655,"twenty":-54.881886,"median":-46.751052,"eighty":-40.312191,"marketCap":36824843832},{"date":"2024-05-03","current":-70.050704,"twenty":-55.277405,"median":-46.894686,"eighty":-40.440284,"marketCap":35948061836},{"date":"2024-05-10","current":-80.537958,"twenty":-55.535893,"median":-47.299854,"eighty":-40.706984,"marketCap":41427949311},{"date":"2024-05-17","current":-72.846762,"twenty":-56.640749,"median":-47.434905,"eighty":-40.885351,"marketCap":37416671679},{"date":"2024-05-24","current":-76.490072,"twenty":-57.838988,"median":-47.480121,"eighty":-41.121673,"marketCap":39198277014},{"date":"2024-05-31","current":-74.804992,"twenty":-59.45269,"median":-48.0541,"eighty":-41.186166,"marketCap":38373753847},{"date":"2024-06-07","current":-77.551054,"twenty":-62.567703,"median":-48.422639,"eighty":-41.217553,"marketCap":39733102851},{"date":"2024-06-14","current":-71.048454,"twenty":-63.220056,"median":-48.609184,"eighty":-41.232055,"marketCap":36368156956},{"date":"2024-06-21","current":-75.38559,"twenty":-65.709636,"median":-48.654461,"eighty":-41.23344,"marketCap":38507460307},{"date":"2024-06-28","current":-72.361795,"twenty":-70.050704,"median":-48.790889,"eighty":-41.25919,"marketCap":36947551614},{"date":"2024-07-05","current":-71.32983,"twenty":-70.110492,"median":-48.913989,"eighty":-41.293743,"marketCap":36412725776},{"date":"2024-07-12","current":-64.338068,"twenty":-69.786991,"median":-49.290918,"eighty":-41.483815,"marketCap":32891789012},{"date":"2024-07-19","current":-64.816339,"twenty":-69.10708,"median":-50.290098,"eighty":-41.560643,"marketCap":33136917521},{"date":"2024-07-26","current":-64.836994,"twenty":-68.943217,"median":-50.396598,"eighty":-41.836002,"marketCap":33270623980},{"date":"2024-08-02","current":-67.177788,"twenty":-68.832021,"median":-50.583009,"eighty":-41.911922,"marketCap":34451697705},{"date":"2024-08-09","current":-67.337335,"twenty":-68.832021,"median":-50.91108,"eighty":-41.921641,"marketCap":34763679444},{"date":"2024-08-16","current":-69.468586,"twenty":-68.832021,"median":-51.098991,"eighty":-41.970061,"marketCap":35877899939},{"date":"2024-08-23","current":-143.952492,"twenty":-69.519081,"median":-51.282062,"eighty":-42.023931,"marketCap":36568716645},{"date":"2024-08-30","current":-142.905377,"twenty":-70.543671,"median":-51.775379,"eighty":-42.069838,"marketCap":36546432236},{"date":"2024-09-06","current":-147.713941,"twenty":-71.622574,"median":-52.451442,"eighty":-42.229208,"marketCap":37794359190},{"date":"2024-09-13","current":-159.71572,"twenty":-72.235174,"median":-53.058458,"eighty":-42.319371,"marketCap":40758185707},{"date":"2024-09-20","current":-153.295015,"twenty":-72.624329,"median":-53.663008,"eighty":-42.346401,"marketCap":39354267883},{"date":"2024-09-27","current":-152.378595,"twenty":-73.54444,"median":-54.299669,"eighty":-42.364187,"marketCap":39354267883},{"date":"2024-10-04","current":-188.785359,"twenty":-74.133327,"median":-54.381491,"eighty":-42.385888,"marketCap":48535444762},{"date":"2024-10-10","current":-168.292174,"twenty":-74.96999,"median":-54.488817,"eighty":-42.420555,"marketCap":42986626697},{"date":"2024-10-18","current":-169.261982,"twenty":-75.395206,"median":-54.742682,"eighty":-42.48514,"marketCap":43008911107},{"date":"2024-10-25","current":-173.131782,"twenty":-76.300948,"median":-55.181976,"eighty":-42.60999,"marketCap":43989425142},{"date":"2024-11-01","current":-155.135166,"twenty":-77.964709,"median":-55.298647,"eighty":-42.767052,"marketCap":39443405523},{"date":"2024-11-08","current":-154.553256,"twenty":-78.843611,"median":-55.532894,"eighty":-42.819467,"marketCap":38997717325},{"date":"2024-11-15","current":-143.716763,"twenty":-80.792913,"median":-56.569783,"eighty":-42.897746,"marketCap":35989321988},{"date":"2024-11-22","current":-149.571879,"twenty":-86.542136,"median":-57.071537,"eighty":-43.077872,"marketCap":37437808632},{"date":"2024-11-29","current":-163.214034,"twenty":-139.660525,"median":-57.926605,"eighty":-43.27892,"marketCap":40825038936},{"date":"2024-12-06","current":-164.492389,"twenty":-143.07608,"median":-58.601892,"eighty":-43.427612,"marketCap":41047883035},{"date":"2024-12-13","current":-167.859925,"twenty":-143.961595,"median":-59.46824,"eighty":-43.489321,"marketCap":41805552972},{"date":"2024-12-20","current":-160.518216,"twenty":-146.054141,"median":-61.493522,"eighty":-43.569737,"marketCap":39799956081},{"date":"2024-12-27","current":-154.616488,"twenty":-147.398806,"median":-62.556972,"eighty":-43.707223,"marketCap":38306900618},{"date":"2025-01-03","current":-146.467928,"twenty":-147.580179,"median":-62.909234,"eighty":-43.769457,"marketCap":36323588137},{"date":"2025-01-10","current":-149.189796,"twenty":-147.713941,"median":-63.270129,"eighty":-43.89543,"marketCap":36858413974},{"date":"2025-01-17","current":-146.545949,"twenty":-148.128618,"median":-63.821936,"eighty":-43.999852,"marketCap":36234450497},{"date":"2025-01-24","current":-151.096908,"twenty":-148.795989,"median":-64.223738,"eighty":-44.022873,"marketCap":37593799501},{"date":"2025-01-28","current":-144.751587,"twenty":-148.750633,"median":-64.3181,"eighty":-44.025895,"marketCap":36203787461},{"date":"2025-02-07","current":-162.755483,"twenty":-148.864023,"median":-64.816339,"eighty":-44.095348,"marketCap":40476425278},{"date":"2025-02-14","current":-166.856795,"twenty":-150.654332,"median":-65.202788,"eighty":-44.112421,"marketCap":41476404342},{"date":"2025-02-21","current":-194.414734,"twenty":-151.676932,"median":-65.382992,"eighty":-44.172115,"marketCap":48498984584},{"date":"2025-02-28","current":-211.14481,"twenty":-152.24965,"median":-65.712478,"eighty":-44.17615,"marketCap":52498900839},{"date":"2025-03-07","current":-225.41295,"twenty":-152.905086,"median":-66.309677,"eighty":-44.219461,"marketCap":56271549124},{"date":"2025-03-14","current":-227.151092,"twenty":-153.295015,"median":-66.812487,"eighty":-44.308071,"marketCap":56726085062},{"date":"2025-03-21","current":-236.708664,"twenty":-154.553256,"median":-67.337335,"eighty":-44.550078,"marketCap":59089671940},{"date":"2025-03-28","current":-231.805328,"twenty":-155.61149,"median":-67.803663,"eighty":-44.648429,"marketCap":66180441600},{"date":"2025-04-03","current":-246.46154,"twenty":-156.727441,"median":-67.952396,"eighty":-44.882152,"marketCap":70225812000},{"date":"2025-04-11","current":-242.489155,"twenty":-158.779779,"median":-68.515098,"eighty":-45.005591,"marketCap":68634936000},{"date":"2025-04-17","current":-228.611836,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"marketCap":64862287200}],"updateTime":1745219898814}}}